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cal features in patients with cervical artery dissection (CeAD) 
with other TIA or ischemic stroke (IS) patients of similar age 
and sex.  Methods: We analysed demographic, clinical and 
risk factor profiles in TIA and IS patients  ≤ 55 years of age with 
and without CeAD in the large European, multi-centre, 
Stroke In young FAbry Patients 1 (sifap1) study. Patients 
were further categorised according to age (younger: 18–44 
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 Abstract 
 Background: Patients with carotid artery dissection (CAD) 
have been reported to have different vascular risk factor pro-
files and clinical outcomes to those with vertebral artery dis-
section (VAD). However, there are limited data from recent, 
large international studies comparing risk factors and clini-
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years; middle-aged: 45–55 years), sex, and site of dissection. 
 Results: Data on the presence of dissection were available in 
4,208 TIA and IS patients of whom 439 (10.4%) had CeAD: 
196 (50.1%) had CAD, 195 (49.9%) had VAD, and 48 had mul-
tiple artery dissections or no information regarding the dis-
sected artery. The prevalence of CAD was higher in women 
than in men (5.9 vs. 3.8%, p < 0.01), whereas the prevalence 
of VAD was similar in women and men (4.6 vs. 4.7%, n.s.). Pa-
tients with VAD were younger than patients with CAD (me-
dian = 41 years (IQR = 35–47 years) versus median = 45 years 
(IQR = 39–49 years); p < 0.01). At stroke onset, about twice as 
many patients with either CAD (54.0 vs. 23.1%, p < 0.001) or 
VAD (63.4 vs. 36.6%, p < 0.001) had headache than patients 
without CeAD and stroke in the anterior or posterior circula-
tion, respectively. Compared to patients without CeAD, hy-
pertension, concomitant cardiovascular diseases and a pat-
ent foramen ovale were significantly less prevalent in both 
CAD and VAD patients, whereas tobacco smoking, physical 
inactivity, obesity and a family history of cerebrovascular dis-
eases were found less frequently in CAD patients, but not in 
VAD patients. A history of migraine was observed at a similar 
frequency in patients with CAD (31%), VAD (27.8%) and in 
those without CeAD (25.8%).  Conclusions: We identified 
 clinical features and risk factor profiles that are specific to 
young patients with CeAD, and to subgroups with either 
CAD or VAD compared to patients without CeAD. Therefore, 
our data support the concept that certain vascular risk fac-
tors differentially affect the risk of CAD and VAD. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 The incidence of cervical artery dissection (CeAD) is 
estimated to be 3–5/100,000/year  [1, 2] and more often 
affects carotid than vertebral arteries (1.87–5.0 vs. 0.97–
1.5/100,000/year)  [1, 3, 4] . CeAD is recognised as a very 
important cause of TIA and ischaemic stroke (IS) in the 
young and is the underlying pathomechanism in 11–18% 
of patients under 55 years of age  [1, 5, 6] .
 The assumption that TIA and IS patients with CeAD 
tend to have fewer vascular risk factors than other stroke 
subtypes is supported by data from recent multicentre reg-
istries  [7, 8] . These registries also suggest different risk fac-
tor profiles, clinical presentations, and clinical outcomes 
in patients with carotid artery dissection (CAD) and those 
with vertebral artery dissection (VAD). Patients with CAD 
were found to be a few years older, more often male and 
less commonly smokers, while patients with VAD more 
often suffered from thunderclap headache, neck pain, and 
IS instead of TIA  [7–9] . However, data comparing risk fac-
tors and clinical features in TIA or IS patients with CeAD 
overall, and in CAD and VAD subgroups with other ae-
tiological subtypes of similar age and sex are limited.
 Therefore, we sought to compare the clinical charac-
teristics and risk factor profiles in young TIA and IS pa-
tients with and without CeAD, and among subgroups of 
patients with CAD and VAD versus those without CeAD 
in a large population with newly diagnosed cerebrovascu-
lar disease in Europe.
 Methods 
 The Stroke In young Fabry Patients 1 (sifap1) study was a pro-
spective, international multicentre study to establish the preva-
lence of Fabry’s disease in young patients with cerebrovascular 
events (CVE) in Europe  [10] . A total of 5,023 patients were re-
cruited between April 2007 and January 2010 at 47 centres in 15 
European countries. Patients were included if they had experi-
enced a CVE within the preceding 3 months, were aged 18–55 
years, and had cerebral magnetic resonance imaging (MRI) within 
1 month of inclusion. CVE included TIA (i.e., symptoms <24 h 
without infarction or haemorrhage on MRI or CT) and IS (i.e., 
symptoms >24 h without haemorrhage on MRI or CT at stroke 
onset). Diagnostic work up was performed in accordance with the 
European Stroke Organisation Guidelines  [11] . The study was per-
formed according to the Helsinki Declaration and approved by the 
Ethics Committees at the lead study centre (Rostock) and at each 
study site. All patients or their legal representatives gave written 
informed consent to participate.
 In this sub-study of sifap1, we compared the distinctive features 
of TIA and IS patients with and without CeAD regarding the differ-
ential involvement of cervical arteries, presenting symptoms, and 
vascular risk factors. For analyses of clinical presentation, we com-
pared CAD patients with anterior circulation stroke patients with-
out CeAD and VAD patients with posterior circulation stroke pa-
tients without CeAD. Stroke territory was defined according to MRI. 
 Presenting symptoms were assessed using dichotomized ques-
tionnaires that were completed by experienced neurologists and 
stroke physicians at each centre. Risk factors were classified ac-
cording to their strength of evidence and potential for modifica-
tion as described in the current guidelines of the American Stroke 
Association  [12] and as described previously by sifap1 investiga-
tors  [13] .
 Patients with CeAD were identified from the TOAST subgroup 
attributed to ‘acute CVE of other determined aetiology’. The diag-
nosis was confirmed by MRI, MR-angiography, ultrasonography 
or CT-angiography, based on the judgement of the treating neu-
rologists, stroke physicians and neuroradiologists at each study 
centre. In addition, all MRI images transferred to the database 
were interpreted by the central imaging committee, which was 
blinded for the patients’ diagnosis. Depending on the applied im-
aging modality, diagnostic characteristics of CeAD included the 
presence of intramural haematoma, long tapering stenosis, at 
times ending in an occlusion, intimal flap, or double lumen of the 
carotid or vertebral arteries  [14] .
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 All patients with other TIA or IS subtypes were classified as 
having had a TIA or IS without CeAD for the purpose of this sub-
study of sifap1.
 Statistical Analyses 
 Patients with CeAD were categorised into age groups (‘young-
er’: 18–44 years and ‘middle-aged’: 45–55 years), according to their 
sex (male or female), and their dissected artery (ICA or VA). Fre-
quencies, means and medians in different characteristics were 
compared between sexes, young and middle-aged patients with 
CAD or VAD versus those without CeAD. Logistic regression 
models with random intercepts were performed to account for 
centre heterogeneity. A two-sided p value <0.05 was considered 
statistically significant; no adjustment for multiple testing was ap-
plied in this observational study. Thus, significances may not be 
interpreted as strictly confirmatory. Statistical analyses were per-
formed with SPSS 22.0 and SAS 9.3.
 Results 
 Among 5,023 patients enrolled in sifap1, 4,464 had 
TIA or IS. We had to exclude 256 patients from our anal-
ysis due to missing data regarding the presence or absence 
of CeAD. Subsequently, we analysed data of 4,208 pa-
tients (2,500 men, 1,708 women, 1,692 young, 2,516 mid-
dle-aged) and identified 439 (10.4%) patients with TIA 
(n = 118) and IS (n = 321) with CeAD and 3,769 patients 
without CeAD. Diagnosis of dissection was made by 
MRI/MR-angiography (n = 279, 63.6%), ultrasonography 
(n = 255, 58.1%), and CT-angiography (n = 15, 3.4%), 
(some patients had multiple imaging modalities used to 
confirm diagnosis). There was a nonsignificant trend for 
women (204, 11.9%) to be more frequently affected by 
dissection than men (235, 9.4%, p = 0.058 age-adjusted). 
The prevalence of CeAD was almost twice as high in 
young (246 of 1,692, 14.5%) than in middle-aged patients 
(193 of 2,516, 7.7%, p < 0.0001). Overall, the median 
score on the modified Rankin Scale (mRS), the Barthel 
Index (BI) and National Institute of Health Stroke Scale 
(NIHSS) scores obtained during the acute phase of stroke 
indicated quite a low degree of impairment in the entire 
sifap1 cohort ( tables 1 ,  2 ). In patients with CAD, neuro-
logical deficits were slightly more impairing than in pa-
tients without CeAD according to mRS (median = 2, in-
terquartile range (IQR) 1–4 vs. 2, IQR 1–3, p < 0.001) and 
BI (median = 90, IQR 26–100 vs. 100, IQR 70–100, p < 
0.001), while there was no relevant difference in patients 
with VAD.
 There were 16 (3.6%) patients with multiple artery dis-
sections and 32 (7.3%) with missing information on the 
affected cervical artery. Among the remaining 391 pa-
tients with CeAD in whom precise data were available 
and in whom either the carotid or the vertebral artery was 
involved, the proportion of CAD (n = 196, 50.1%) and 
VAD (n = 195, 49.9%) was similar.
 CAD was more prevalent in women than in men (5.9 
vs. 3.8%, p < 0.01), whereas VAD was comparable preva-
lent in women and men (4.6 vs. 4.7%, n.s.). VAD patients 
were younger than CAD patients (median = 41 years 
(IQR = 35–47 years) versus median = 45 years (IQR = 
39–49 years); p < 0.01). Furthermore, TIA and IS caused 
by VAD less frequently had a history of prior TIA than 
those caused by CAD (3.7 vs. 10.0%, p < 0.05, data not 
shown) or those caused by a non-CeAD aetiology (3.7 vs. 
9.5%, p < 0.05). A direct comparison of well-documented 
modifiable and non-modifiable risk factors between CAD 
and VAD patients revealed only a significantly higher 
prevalence of LDL-cholesterol levels  ≥ 3.37 mmol/l in 
VAD patients (39 vs. 20%, p < 0.01, data not shown). Dif-
ferences in the prevalence of well-documented modifi-
able and non-modifiable risk factors between patients 
without CeAD and those with CAD and VAD, respec-
tively, are shown in  figure 1 a and b. Compared to patients 
without CeAD, hypertension, concomitant cardiovascu-
lar diseases and a patent foramen ovale were observed less 
frequently in both CAD and VAD patients, whereas to-
bacco smoking, physical inactivity, obesity and a family 
history of cerebrovascular diseases were significantly less 
prevalent in patients with CAD, but not in patients with 
VAD ( tables 1 ,  2 ;  fig. 1 a, b). A history of migraine was 
similar in patients with CAD (31%), VAD (27.8%) and in 
those without CeAD (25.8%). High-risk alcohol con-
sumption as defined as consuming >5 alcoholic drinks/
day at least once/month within the previous year was an 
important risk factor in young male stroke patients with-
out CeAD (42.7%), but was less frequently seen in male 
CAD (33%) and VAD patients (32.1%; p value for interac-
tion between sex and high-risk alcohol consumption was 
<0.05 in VAD, but not significant in CAD;  tables 1 ,  2 ).
 For comparison of the presenting symptoms at stroke 
onset between patients with CAD or VAD and non-
CeAD patients, we restricted our analysis to those non-
CeAD stroke patients with an MRI-proven infarction of 
either the anterior (n = 1,493) or the posterior circulation 
(n = 547). Headache was about twice as common in pa-
tients with CAD (54.0 vs. 23.1%, p < 0.001) and VAD 
(63.4 vs. 36.6%, p < 0.001) compared to patients without 
CeAD and stroke in the anterior and posterior circula-
tion, respectively ( tables 3 ,  4 ). Furthermore, loss of con-
sciousness, nausea/vomiting, and visual field symptoms 
were more frequent in patients with CAD than in patients 
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with anterior circulation stroke without CeAD, while 
nausea/vomiting and vertigo were more common in pa-
tients with VAD than in non-CeAD patients with poste-
rior circulation stroke.
 Discussion 
 This is the first study that systematically describes dis-
parities of risk factor profiles and clinical characteristics 
between male and female, younger and middle-aged TIA 
and IS patients with CAD and VAD and compares them 
with a contemporaneous cohort of non-CeAD IS and TIA 
patients. Previous studies, which directly compared CAD 
with VAD, reported that CAD was detected about 1.7–2.2 
times more frequently than VAD and that patients with 
CAD were on average 5 years older and showed a male 
preponderance of 53–57%  [7, 9, 15, 16] . In agreement 
with these data, patients with CAD were 4 years older in 
sifap1 than those with VAD. However, we found a male 
preponderance in VAD patients but not in CAD patients, 
and a similar prevalence of patients with VAD or CAD. 
Our study differs from previous studies in terms of enroll-
ing only patients with TIA and IS, whereas others includ-
ed also a substantial proportion of patients who presented 
exclusively with local symptoms of CeAD but not with 
cerebrovascular events. The higher proportion of CAD 
patients with only local symptoms compared with VAD 
patients  [7, 9] may in part explain the almost equal per-
centage of CAD (51%) and VAD (49.9%) in our study. A 
similar percentage of VAD and CAD like in our study was 
also reported from the Dijon Stroke Registry, which also 
included only patients with TIA and IS  [1] . Another im-
portant reason for a higher prevalence of VAD than ex-
pected may be a greater awareness of dissection, espe-
cially in younger patients, and improvements in diagnos-
tic tools and access to MRI during the last decade. This 
has also been observed in a population-based study from 
the Mayo Clinic, where the incidence of CAD exceeded 
that of VAD by a factor of 4 before 1994, whereas the fre-
quency of CAD and VAD was similar after 1994  [3] .
 As reported in earlier studies  [8, 17, 18] , most vascular 
risk factors were also less common in patients with CAD 
or VAD than in patients without CeAD in sifap1 ( tables 3 , 
 4 ). Prior studies comparing patients with CAD and VAD 
did not report significant differences regarding the prev-
alence of vascular risk factors between CAD and VAD 
except for a higher prevalence of current smoking in pa-
tients with VAD  [7, 9, 15] . Comparing CAD and VAD 
patients with TIA and IS patients without CeAD of simi-
lar age and sex, we found that most of the well-document-
ed and modifiable vascular risk factors were significantly 
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less frequent in patients with CAD, while hypertension, 
diabetes and concomitant cardiovascular disease were 
also significantly less frequent in VAD patients compared 
to patients without CeAD. Although VAD patients were 
significantly younger than CAD patients, the percentage 
of patients with increased levels of most risk factors was 
higher in VAD than in CAD patients. Specifically, high 
LDL-cholesterol was twice as frequent in patients with 
VAD as in patients with CAD and even more frequently 
seen in male VAD patients than in patients without 
CeAD. Furthermore, patients with VAD less frequently 
had a history of prior TIA or other cerebrovascular events 
than patients with CAD or without CeAD.
 Several prior case-control studies and registries identi-
fied migraine as an independent risk factor for CeAD  [17, 
19] . In sifap1, migraine was equally common in TIA and 
IS patients with CAD, VAD or without CeAD patients. 
Furthermore, the reported migraine prevalence of 29% in 
CeAD patients and distribution between the sexes was in 
line with previous case series of young stroke patients 
overall (17.2–26.1%)  [20, 21] and specifically in those 
with CeAD (25–35.7%)  [17, 22] . Thus, we cannot confirm 
an association of migraine and the occurrence of CAD or 
VAD.
 Consistent with previous reports  [1, 7, 9, 22] , headache 
was the symptom that most commonly separates CeAD 
patients from patients without CeAD. In VAD patients, 
headache was frequently accompanied by nausea, vomit-
ing and vertigo. This observation emphasises that the 
combination of focal symptoms with headache should 
prompt physicians to take CeAD into account. It is, how-
ever, also important to emphasise that 23.1 and 36.6% of 
patients without dissection and IS in the anterior and pos-
terior circulation, respectively, also had headache  [23] , 
which is more frequent than what was reported in earlier 
stroke registries  [24] .
 Patients with CAD had a higher mRS and a lower BI 
in the acute phase after stroke indicating that patients 
with CAD were more severely impaired than those with-
out CeAD. As shown before in other CeAD registries  [7, 
9] , the NIHSS is less valuable in assessing the severity of 
strokes affecting the brainstem and the cerebellum. This 
is the most likely reason for the lower NIHSS of VAD pa-
tients as compared to CeAD patients.
 Our study has strengths and limitations. The strengths 
of sifap1 are the prospective nature of the recruitment of 
patients in 47 multinational study centres, the standardi-
sation of data assessment, and a blinded central analysis 
of MRI-images. The limitations are as follows: (1) The 
need for participants’ informed consent or assent from a Ta
b
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legal representative might have led to exclusion of some 
more severely affected patients although severe stroke 
was not an exclusion criterion in sifap1. This might part-
ly explain the overall low median NIHSS-scores in sifap1, 
but does not in any way invalidate the main finding of this 
study. (2) Similar to the majority of studies on CeAD, 
 sifap1 did not include a control group of age- and sex-
matched healthy individuals from the same catchment 
area as the sifap1 patients. Therefore, we cannot com-
ment on associations between certain risk factors and the 
presence of CeAD in CeAD patients versus healthy con-
trols. However, we did have the unique opportunity of 
comparing profiles in patients with CeAD with contem-
poraneously recruited young patients without CeAD. (3) 
Ultrasonography and CT-angiography did not undergo 
central reading. (4) We have limited information on trau-
ma preceding CeAD to separate spontaneous dissection 
or dissection associated with minor trauma from those 
caused by relevant trauma. However, as patients were re-
cruited from regular stroke units but not from neurosur-
gical or surgical intensive care units, the number of pa-
tients with CeAD caused by relevant trauma included 
into sifap1 is considered being very low and not influenc-
ing our statistical analyses. (5) Our patients are predomi-
nantly European Caucasians and application of our data 
is only valid for this distinct ethnic group and geographic 
locations included in this large multicentre collaborative 
study. Nevertheless, our findings provide invaluable in-
sight into the clinical profiles of patients with CAD and 
VAD in Europe.
 In summary, the present analysis of the sifap1 study 
has expanded our knowledge base by facilitating identifi-
cation of different clinical features and risk factor profiles 
that are specific to young patients with CeAD, and to sub-
groups with either CAD or VAD compared with patients 
without CeAD. Our findings support the concept that 
certain vascular risk factors differentially affect the risk of 
CAD and VAD, and support the design of future, pro-
spective studies and trials that should analyse data from 
CAD and VAD patient subgroups separately.
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